

Investing in Ophthalmology

Developing Treatments to Prevent Blindness

Millions of people worldwide have significant visual disability. Many of these patients are afflicted with diseases that may become treatable over the next 10 to 20 years. Major causes of blindness and visual disability include cataracts and glaucoma in the front of the eye and diabetic retinopathy, age-related macular degeneration and retinitis pigmentosa in the back of the eye. Millions of people become blind each year as a result of these maladies. With perhaps only cataract patients having what could be considered a permanent solution for their disease and an increasingly aging population, the importance of eye care is expected to increase politically, economically and personally.

Research Corporation Technologies has targeted ophthalmology as an area of large unmet medical need and are actively accepting new opportunities. We are interested specifically in:

- Preclinical and early clinical candidates targeted to treat retinal degenerative diseases of the back of the eye
- Novel drugs or ophthalmologic formulations with solid preclinical or clinical data

RCT has assets of more than \$300 million to advance technology development activities through flexible, long-term investment options. We focus our investments on opportunities that promise patented biomedical products with a clear competitive advantage.

If you are a start-up or early-stage company, RCT invests in companies whose technologies have the potential to become significant biomedical products through our RCT BioVentures program. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.

If you have a new therapeutic, RCT can help it move from bench to bedside. We can provide money and management to advance a promising new drug into clinical trials through a variety of business arrangements, including licenses and development partnerships.

If your company or technology meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.

